Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients

Heng Jung Hsu, Mai Szu Wu

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH) is a common cardiovascular disorder and an independent risk factor for cardiovascular death in dialysis patients. Hyperphosphatemia is associated with LVH. Previous studies have shown that fibroblast growth factor 23 (FGF23), which has an important role in phosphate metabolism, is elevated in chronic hemodialysis patients. OBJECTIVES: The aim of this study is to determine the association of FGF23 and LVH and the prognostic value of FGF23 in chronic hemodialysis patients. MATERIALS AND METHODS: One hundred twenty-four end-stage renal disease patients were evaluated for LVH by echocardiography. Serum FGF23 levels were measured using a commercial enzyme-linked immunosorbent assay kit. RESULTS: Patients with LVH were more likely to have poor urea clearance (Kt/V), higher systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease. LVH was also associated with higher levels of FGF23. Multivariate analysis indicated that FGF23 level, systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease remained correlated with LVH. This suggested that serum FGF23 level is independently associated with LVH in our hemodialysis patients. Cox analysis indicated no significant difference in risk of death for patients with elevated levels of FGF23. CONCLUSION: LVH has a high prevalence in hemodialysis patients, and FGF23 is independently associated with LVH but is not a predictor for short-term prognosis (2-year follow-up).

Original languageEnglish
Pages (from-to)116-122
Number of pages7
JournalAmerican Journal of the Medical Sciences
Volume337
Issue number2
DOIs
Publication statusPublished - Feb 2009
Externally publishedYes

Fingerprint

Left Ventricular Hypertrophy
Renal Dialysis
Blood Pressure
Comorbidity
Coronary Artery Disease
Diabetes Mellitus
fibroblast growth factor 23
Hyperphosphatemia
Serum
Chronic Kidney Failure
Echocardiography
Urea
Dialysis
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Phosphates
Hypertension

Keywords

  • End-stage renal disease
  • ESRD
  • FGF23
  • Fibroblast growth factor 23
  • Hemodialysis
  • Left ventricular hypertrophy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fibroblast growth factor 23 : A possible cause of left ventricular hypertrophy in hemodialysis patients. / Hsu, Heng Jung; Wu, Mai Szu.

In: American Journal of the Medical Sciences, Vol. 337, No. 2, 02.2009, p. 116-122.

Research output: Contribution to journalArticle

@article{561cff5eea9e4fc8aa7c9c634e3cd342,
title = "Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients",
abstract = "BACKGROUND: Left ventricular hypertrophy (LVH) is a common cardiovascular disorder and an independent risk factor for cardiovascular death in dialysis patients. Hyperphosphatemia is associated with LVH. Previous studies have shown that fibroblast growth factor 23 (FGF23), which has an important role in phosphate metabolism, is elevated in chronic hemodialysis patients. OBJECTIVES: The aim of this study is to determine the association of FGF23 and LVH and the prognostic value of FGF23 in chronic hemodialysis patients. MATERIALS AND METHODS: One hundred twenty-four end-stage renal disease patients were evaluated for LVH by echocardiography. Serum FGF23 levels were measured using a commercial enzyme-linked immunosorbent assay kit. RESULTS: Patients with LVH were more likely to have poor urea clearance (Kt/V), higher systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease. LVH was also associated with higher levels of FGF23. Multivariate analysis indicated that FGF23 level, systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease remained correlated with LVH. This suggested that serum FGF23 level is independently associated with LVH in our hemodialysis patients. Cox analysis indicated no significant difference in risk of death for patients with elevated levels of FGF23. CONCLUSION: LVH has a high prevalence in hemodialysis patients, and FGF23 is independently associated with LVH but is not a predictor for short-term prognosis (2-year follow-up).",
keywords = "End-stage renal disease, ESRD, FGF23, Fibroblast growth factor 23, Hemodialysis, Left ventricular hypertrophy",
author = "Hsu, {Heng Jung} and Wu, {Mai Szu}",
year = "2009",
month = "2",
doi = "10.1097/MAJ.0b013e3181815498",
language = "English",
volume = "337",
pages = "116--122",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Fibroblast growth factor 23

T2 - A possible cause of left ventricular hypertrophy in hemodialysis patients

AU - Hsu, Heng Jung

AU - Wu, Mai Szu

PY - 2009/2

Y1 - 2009/2

N2 - BACKGROUND: Left ventricular hypertrophy (LVH) is a common cardiovascular disorder and an independent risk factor for cardiovascular death in dialysis patients. Hyperphosphatemia is associated with LVH. Previous studies have shown that fibroblast growth factor 23 (FGF23), which has an important role in phosphate metabolism, is elevated in chronic hemodialysis patients. OBJECTIVES: The aim of this study is to determine the association of FGF23 and LVH and the prognostic value of FGF23 in chronic hemodialysis patients. MATERIALS AND METHODS: One hundred twenty-four end-stage renal disease patients were evaluated for LVH by echocardiography. Serum FGF23 levels were measured using a commercial enzyme-linked immunosorbent assay kit. RESULTS: Patients with LVH were more likely to have poor urea clearance (Kt/V), higher systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease. LVH was also associated with higher levels of FGF23. Multivariate analysis indicated that FGF23 level, systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease remained correlated with LVH. This suggested that serum FGF23 level is independently associated with LVH in our hemodialysis patients. Cox analysis indicated no significant difference in risk of death for patients with elevated levels of FGF23. CONCLUSION: LVH has a high prevalence in hemodialysis patients, and FGF23 is independently associated with LVH but is not a predictor for short-term prognosis (2-year follow-up).

AB - BACKGROUND: Left ventricular hypertrophy (LVH) is a common cardiovascular disorder and an independent risk factor for cardiovascular death in dialysis patients. Hyperphosphatemia is associated with LVH. Previous studies have shown that fibroblast growth factor 23 (FGF23), which has an important role in phosphate metabolism, is elevated in chronic hemodialysis patients. OBJECTIVES: The aim of this study is to determine the association of FGF23 and LVH and the prognostic value of FGF23 in chronic hemodialysis patients. MATERIALS AND METHODS: One hundred twenty-four end-stage renal disease patients were evaluated for LVH by echocardiography. Serum FGF23 levels were measured using a commercial enzyme-linked immunosorbent assay kit. RESULTS: Patients with LVH were more likely to have poor urea clearance (Kt/V), higher systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease. LVH was also associated with higher levels of FGF23. Multivariate analysis indicated that FGF23 level, systolic blood pressure, and comorbidity of diabetes mellitus and coronary artery disease remained correlated with LVH. This suggested that serum FGF23 level is independently associated with LVH in our hemodialysis patients. Cox analysis indicated no significant difference in risk of death for patients with elevated levels of FGF23. CONCLUSION: LVH has a high prevalence in hemodialysis patients, and FGF23 is independently associated with LVH but is not a predictor for short-term prognosis (2-year follow-up).

KW - End-stage renal disease

KW - ESRD

KW - FGF23

KW - Fibroblast growth factor 23

KW - Hemodialysis

KW - Left ventricular hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=61849155234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849155234&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e3181815498

DO - 10.1097/MAJ.0b013e3181815498

M3 - Article

C2 - 19214027

AN - SCOPUS:61849155234

VL - 337

SP - 116

EP - 122

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 2

ER -